Brief: Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease
28/04/2022 13:29
April 28 (Reuters) - Vaxxinity Inc VAXX.O :
* VAXXINITY COMPLETES ENROLLMENT IN PART B OF UB-312 PHASE 1
CLINICAL TRIAL FOR PARKINSON'S DISEASE
Source text for Eikon: ID:nGNX7gpkWR
Further company coverage: VAXX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaxxinity
See all newsU.S. STOCKS ON THE MOVE-EV stocks, Salesforce, Verizon
Brief: Vaxxinity Announces Intention To Voluntarily Delist And Deregister Its Class A Common Stock
Brief: Vaxxinity Announces Intention To Voluntarily Delist And Deregister Its Class A Common Stock
Brief: Vaxxinity Q4 Net Income USD -11.392 Million
Vaxxinity Inc expected to post a loss of 10 cents a share - Earnings Preview